
    
      A double-blind, randomized, placebo-controlled, parallel group study to investigate the
      efficacy, safety, tolerability, pharmacokinetics, and pharmacodynamics of SB-497119-GR, a
      thrombopoietin receptor agonist, administered at 30, 50, and 75 mg as oral tablets once-daily
      for 6 weeks to adult male and female subjects with refractory, chronic immune
      thrombocytopenia purpura
    
  